Hypogammaglobulinemia Clinical Trials

A listing of Hypogammaglobulinemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 19 clinical trials
Efficacy and Safety Study of Mavorixafor in Participants With Warts Hypogammaglobulinemia Infections and Myelokathexis (WHIM) Syndrome

This study has a double-blind, placebo-controlled Randomized Period and an Open-Label extension Period. The primary objective of the Randomized Period is to demonstrate the efficacy of mavorixafor in participants with WHIM syndrome as assessed by increasing levels of circulating neutrophils compared with placebo, and relative to a clinically meaningful threshold. …

  • 07 Jun, 2021
  • 24 locations
Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%

This is a Phase 3, multicenter, randomized, controlled, parallel-group, open-label study to evaluate the effects of plasma exchange using human serum albumin 5% (PE-A 5%) in acute-on-chronic liver failure (ACLF) subjects. The study will involve approximately 40 study centers in the United States, Canada, and Europe with expertise in the …

plasma exchange
  • 07 May, 2021
  • 44 locations
Double-blind Randomized Placebo-controlled Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia

chronic lymphocytic leukemia
primary infection
  • 23 Jul, 2021
  • 38 locations
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

Background WHIMS (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis Syndrome) is caused by various genetic changes that increase the activity of the

granulocyte colony stimulating factor
human papillomavirus
  • 01 Jul, 2021
  • 1 location
Efficacy of COVID-19 Vaccination in Patientstreated With Anti-CD20 for Follicular Lymphoma or Mantle Cell Lymphoma

mantle cell lymphoma (MCL). This treatment is associated with profound and prolonged B lymphopenia, hypogammaglobulinemia and increased infections. Severe forms of COVID-19 on Rituximab with

follicular lymphoma
mantle cell lymphoma
  • 23 Jun, 2021
  • 1 location
Immune Disorder HSCT Protocol

This study hypothesizes that a reduced intensity immunosuppressive preparative regimen will establish engraftment of donor hematopoietic cells with acceptable early and delayed toxicity in patients with immune function disorders. A regimen that maximizes host immune suppression is expected to reduce graft rejection and optimize donor cell engraftment.

granulocyte colony stimulating factor
treatment regimen
  • 24 Jan, 2021
  • 2 locations
Analysis of the Immune Parameters of COVID-19 Infection in Patients With Multiple Myeloma

Among all MM patients included in the cohort at the time of diagnosis of SARS-CoV-2 infection, blood samples will be collected at inclusion, at time of the infection acute phase in the most severe cases (when admitted in intensive care units), and at recovery. The following immune function tests will …

  • 27 Mar, 2021
  • 55 locations
Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease

This is a multicenter non-inferiority study, designed to establish non-inferiority of the study treatment rituximab compared with the comparator ocrelizumab for consecutively included patients (male or female) with active relapsing-remitting multiple sclerosis aged 18-60 years.

  • 25 Mar, 2021
  • 11 locations
Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL

The purpose of this study is to evaluate the safety and efficiency of autologous CD19/CD22 CAR-T lymphocytes in a cohort of pediatric and young adult patients with relapsed /refractory B-lineage acute lymphoblastic leukemia

  • 26 Apr, 2021
  • 1 location
Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia

Our previous study demonstrated that anti-CD19 chimeric antigen receptor in piggyBac transposon-engineered T cells have strong tumor-killing activity in vitro and therapeutic effects in cell line-derived xenograft models, and no obvious side effects such as neurotoxicity and cytokine storm occurred. Therefore, we want to evaluate the safety and clinical effect …

b-cell acute lymphoblastic leukemia
cell transplantation
cancer chemotherapy
multiple myeloma
  • 22 May, 2021
  • 1 location